Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: MRNA.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Moderna (MRNA) Stock Forecast and AI Rating

Original pricing snapshot Sep 18 2026Deep analysis published Sep 21 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

PARTIAL SELL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

SELL ALL

$118

-23.6%

2031

5-Year

PARTIAL SELL

$162

+5.0%

Published batch insight

Cancer Vaccine Euphoria Meets Stark Manufacturing Realities and Multi-Billion Cash Burn

High consensus confirms that landmark melanoma trial results validate messenger RNA in oncology, but sharp divergence surrounds commercial monetization speed. Persistent operating cash burn, bespoke manufacturing bottlenecks, 50% partnership profit sharing, and elevated discount rates indicate substantial intermediate equity valuation headwinds before sustainable profitability.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

J.P. Morgan (Titan), Universal Investor (Polymath), Warren Buffett (Value Purist), Machiavelli (Insider), Michael Burry (Vulture), Elon Musk (Visionary), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Moderna at the forecast anchor (2026-09-18): $10,498 in five years versus $13,892 for S&P 500 benchmark.

Moderna · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Moderna compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 154.04 USD1-year price return: -23.60%5-year price return: +4.98%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	138.47	-10.11%	-10.11%	Speculative euphoria cools as autumn vaccination volumes confirm sluggish endemic booster uptake. Markets confront ongoing multi-hundred-million-dollar operating deficits, driving institutional profit-taking and multiple compression under elevated interest rate conditions.
Q1 2027	126.12	-8.92%	-18.13%	Full-year financial disclosures confirm multi-billion-dollar net losses and cash burn. High Treasury yields penalize long-duration clinical assets, prompting capital rotation away from pre-profit biopharma toward dependable healthcare earnings.
Q2 2027	123.48	-2.09%	-19.84%	Regulatory submission preparations and medical congress abstracts restore speculative interest. Presentation of detailed trial data prompts a tactical relief rally, temporarily counterbalancing structural deficits and ongoing manufacturing buildout expenses.
Q3 2027	117.69	-4.69%	-23.60%	Scrutiny of bespoke manufacturing protocols and reimbursement timelines dampens optimism. Off-season respiratory revenue troughs and persistent cost-of-capital pressures resume intermediate valuation multiple compression across institutional portfolios.
Q4 2027	116.97	-0.61%	-24.06%	Initial regulatory filing acceptances clarify commercial timelines but reveal steep launch infrastructure outlays. Operating expense reductions take hold, yet cash burn remains elevated, keeping equity multiples anchored to fundamental revenue reality.
Q1 2028	117.06	+0.08%	-24.00%	Anticipation of regulatory decisions on personalized oncology therapy drives speculative positioning. Demonstrable operating expense discipline visibly narrows quarterly losses, fostering cautious optimism ahead of critical commercial launch verdicts.
Q2 2028	120.40	+2.85%	-21.84%	Regulatory approval of intismeran autogene in adjuvant melanoma triggers institutional accumulation and milestone inflows. Attention swiftly pivots to complex biopsy-to-infusion logistics, limiting runaway speculative expansion to deliverable launch economics.
Q3 2028	119.08	-1.10%	-22.70%	Early commercial rollout reveals logistical friction and gradual hospital onboarding. Bespoke patient synthesis costs constrain initial gross margins, tempering euphoric sales projections and triggering mild valuation consolidation.
Q4 2028	120.62	+1.30%	-21.69%	Winter respiratory revenue rebounds alongside combination vaccine uptake, while oncology shipments expand. Narrowing operational deficits confirm progress toward cash breakeven, sparking an operational relief rally into year-end.
Q1 2029	120.18	-0.37%	-21.98%	Post-winter seasonal revenue moderation and ongoing clinical development expenses induce minor consolidation. Investors focus on unit cost-of-goods trends and payer reimbursement verification across major regional cancer networks.
Q2 2029	125.73	+4.62%	-18.38%	Manufacturing yield enhancements and automated synthesis workflows compress patient turnaround times. European regulatory clearances broaden the commercial addressable market, reinforcing institutional confidence in long-term earnings durability.
Q3 2029	129.46	+2.97%	-15.95%	Pivotal clinical progress in secondary solid tumor indications expands addressable oncology populations. Commercial revenue steadily absorbs fixed research overhead, supporting modest multiple expansion on verified pipeline diversification.
Q4 2029	134.78	+4.11%	-12.50%	Dual-engine revenue contribution from oncology royalties and mature respiratory franchises pushes quarterly operations near cash breakeven. Attaining this operational turnaround milestone eliminates dilutive financing fears, lifting institutional sentiment.
Q1 2030	137.31	+1.87%	-10.86%	Normal seasonal post-holiday volume decline prompts slight valuation digestion. Valuation remains supported as the business model successfully transitions from a volatile pandemic play to an established commercial specialty oncology producer.
Q2 2030	142.61	+3.86%	-7.42%	Commercial label expansions and international reimbursement agreements drive steady oncology patient volume growth. Expanding manufacturing scale improves gross margins, supporting sustained positive operational cash flow generation.
Q3 2030	145.63	+2.12%	-5.46%	Global sovereign biodefense contracts and routine advance purchase orders establish an insulated commercial revenue floor. Positive operational momentum cushions against broader macroeconomic deceleration and competitive pharmaceutical entrants.
Q4 2030	150.74	+3.51%	-2.14%	Record commercial product shipments across seasonal combination vaccines and oncology infusions deliver sustained GAAP profitability. Demonstrable operating leverage prompts analysts to raise multi-year terminal cash flow projections.
Q1 2031	153.05	+1.53%	-0.64%	Annual financial results confirm full-year operating profitability, completing the corporate turnaround. The equity trades steadily as institutional holders value recurring therapeutic earnings at normalized specialty biopharmaceutical multiples.
Q2 2031	157.84	+3.13%	+2.46%	Next-generation pipeline assets in rare diseases and multivalent vaccines advance into late-stage trials organically. Self-funded development without external capital dependency reinforces balance sheet resilience and defensible competitive moats.
Q3 2031	161.70	+2.45%	+4.98%	The five-year restructuring window concludes with the business operating as an established, cash-generative biotechnology leader. Valuation multiples find lasting equilibrium, anchored by verifiable cash flows and disciplined capital allocation.

Moderna presents a classic valuation disconnect where long-term biological validation outruns near-term shareholder economics. The positive Phase 3 INTerpath-001 melanoma data confirms messenger RNA's therapeutic utility beyond prophylactic vaccines. However, trading at 27.4 times trailing revenue with an annual operating deficit exceeding $3.3 billion, the market prices immediate commercial blockbuster economics while disregarding operational realities. Between clinical validation and projected 2028 operational breakeven lies a multi-year scaling transition constrained by bespoke manufacturing turnaround, a 50% profit-sharing commitment with Merck, and ongoing respiratory demand erosion. In a restrictive monetary regime with 5% risk-free hurdle rates, pre-profit biotechnology assets face severe duration penalties.

Key insights

Bespoke neoantigen synthesis requires patient-specific sequencing, custom formulation, and strict cold-chain logistics, structurally capping gross margins far below pandemic-era windfall benchmarks.
Equal profit sharing with commercialization partner Merck halves attributable oncology cash generation, meaning headline peak product sales translate into modest per-share owner earnings.
Capital preservation via recent zero-coupon convertible issuance extends operating runway into 2028, but converts establish eventual dilution ceilings that limit long-term per-share upside.

Deep Dive

Prevailing market consensus treats the August 2026 Phase 3 melanoma readout as an unassailable de-risking event that instantly transforms the company into a dominant, high-margin oncology monopoly. Retail buyers and sell-side commentary assume rapid, frictionless regulatory approvals and immediate multi-billion-dollar commercial sales. This optimistic crowd narrative anchors on peak pandemic speed, presuming oncology optionality effortlessly overcomes persistent operating deficits and collapsing respiratory booster demand.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially overestimates near-term cash conversion, creating pronounced share overpricing. The analytical edge lies in recognizing that individualized neoantigen therapy is an operationally complex, craft-scale therapeutic requiring multi-week vein-to-vein turnaround, high unit production costs, and an equal profit split with Merck. Furthermore, discounting deferred cash flows at a 5% benchmark rate reveals that current market capitalization already embeds unproven clinical expansions across multiple solid tumors, leaving equity pricing vulnerable to multiple compression.

Repricing catalyst

Granular data disclosures and Biologics License Application filing timelines across 2027 will trigger convergence. When medical congress presentations reveal full overall survival hazard ratios and management discloses commercialization capital expenditures, unit manufacturing costs, and realistic hospital onboarding pacing, expectations will reset. Observable signals will appear when quarterly earnings demonstrate ongoing operational losses despite expense reductions, forcing consensus models to push back self-funded cash breakeven timelines.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime delivers a direct headwind. Benchmark policy rates near 4.00% and ten-year Treasury yields touching 5.0% establish punitive discount rates for long-duration biotechnology assets with negative free cash flow. Higher hurdle rates compress speculative valuation multiples and raise capital costs, punishing cash-burning enterprises regardless of clinical pipeline promise.

Published consensus context

Advisor disagreement

The decisive disagreement centers on the commercial margin structure and cash breakeven velocity of individualized oncology. Optimistic perspectives assume that positive Phase 3 data guarantees rapid regulatory approval, swift automated manufacturing scaling, and operating profitability by 2028. Conversely, conservative forensic views argue that patient-specific neoantigen synthesis imposes rigid cost floors, extended vein-to-vein turnaround times, and equal profit sharing with Merck that defer meaningful free cash flow into the 2030s. The debate will resolve as management discloses detailed manufacturing cost-of-goods and granular INTerpath-001 overall survival hazard ratios during 2027 regulatory filings.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Individualized neoantigen oncology clinical validation: Phase 3 INTerpath-001 trial data demonstrates statistically significant recurrence-free and distant metastasis-free survival in resected melanoma. Partnered with Merck, this breakthrough validates messenger RNA therapeutic efficacy outside infectious disease, unlocking multi-billion-dollar oncology market potential. Clinical validation anchors franchise terminal value and diversifies revenue streams away from seasonal respiratory portfolios over the forecast horizon. Expected impact: +32%.
Merck global oncology commercial partnership: The worldwide collaboration with Merck provides indispensable commercial infrastructure, shared clinical development costs, and immediate hospital distribution access alongside Keytruda. Merck's established oncology salesforce eliminates billions in standalone commercialization buildout outlays. This alliance substantially de-risks execution, accelerates clinical adoption across major cancer centers, and secures high-margin commercial milestone cash inflows through 2031. Expected impact: +22%.
Aggressive research and operating expense rationalization: Executive cost-restructuring initiatives have trimmed annual research expenditures from $4.84 billion toward targeted ranges below $3.5 billion by 2027. Terminating non-core exploratory pipelines, streamlining headcount, and focusing capital exclusively on registrational programs stems catastrophic balance sheet attrition. This operational discipline visibly narrows quarterly operating deficits and establishes a credible glidepath toward cash breakeven. Expected impact: +17%.
Multi-product respiratory commercial portfolio expansion: Regulatory clearance of mFLUSIVA and advancement of combination COVID-flu candidates establish a recurring non-monovalent respiratory base. Bundled seasonal immunizations provide convenient clinical administration across aging demographics. While respiratory markets remain competitive, recurring public health tenders provide an essential non-dilutive revenue baseline, absorbing manufacturing overhead and supporting ongoing clinical oncology research through commercialization. Expected impact: +14%.

Top frictions and headwinds

Excessive valuation multiple speculative overshoot: Trading at 27.4 times trailing twelve-month revenue while generating multi-billion-dollar operating deficits represents severe market overshoot. The price reflects immediate commercial blockbuster realization, ignoring regulatory lead times and initial commercialization lag. As momentum flows dissipate, multiples must compress toward normalized biotechnology peer averages, exerting substantial intermediate valuation drag. Expected impact: -34%.
Bespoke personalized manufacturing cost friction: Individualized neoantigen therapy relies on patient-specific biopsy sequencing, bespoke synthesis, and complex cold-chain logistics within a tight six-week turnaround. This personalized paradigm generates elevated unit cost of goods sold, capping gross margins far below conventional vaccines. Coupled with Merck's 50% profit split, net cash conversion will lag aggressive sell-side expectations. Expected impact: -24%.
Structural respiratory vaccine demand erosion: Widespread public immunization fatigue, diminished mandates, and formidable competition from pharmaceutical incumbents enforce a low ceiling on commercial respiratory revenue. Subdued consumer uptake across monovalent boosters and lagging market share in RSV products compress top-line volume, stranding high-cost manufacturing capacity and depressing return on invested capital across the forecast horizon. Expected impact: -20%.
Restrictive monetary policy and discount penalties: Policy interest rates near 4.00% and ten-year benchmark Treasury yields hovering around 5.0% establish a punishing discount rate for long-duration biotech assets. Elevated capital costs heavily penalize cash-burning enterprises whose primary earnings inflection is deferred past 2028. Restrictive monetary conditions restrict speculative risk tolerance, compressing long-term discounted cash flow valuations. Expected impact: -17%.

Tail risks

Intismeran overall survival statistical failure: Mature overall survival disclosures from the INTerpath-001 melanoma study in 2027 could fail to demonstrate statistically significant lifespans separation despite initial recurrence-free gains. Regulators would impose restrictive label indications and payers would resist premium reimbursement pricing. This clinical shortfall would annihilate the primary growth pillar supporting the company's valuation, triggering catastrophic institutional derating. Strong Phase 2 survival hazard ratios keep trial failure probability below fifty percent. Probability: +32%. Expected impact: -50%.
Adverse federal vaccine schedule restriction: Federal health overseers could alter immunization schedules by early 2027, removing messenger RNA COVID-19 or combination formulations from routine public recommendation guidelines. Such regulatory action would sever automatic insurance reimbursement mandates and severely crush domestic seasonal demand. Resulting top-line destruction would widen quarterly cash burn, rapidly depleting balance sheet liquidity and forcing distressed financing. Ongoing litigation and commercial appeal keep this disruptive political event below fifty percent. Probability: +26%. Expected impact: -38%.

Tail opportunities

Accelerated multi-tumor oncology clinical victory: Phase 3 INTerpath-002 trials in resected non-small cell lung cancer could report statistically significant disease-free survival benefits ahead of schedule by late 2028. Unlocking large-market lung cancer indications expands the addressable patient population fivefold, prompting immediate regulatory priority reviews and triggering over $1.5 billion in commercial milestone payments from Merck. Biological heterogeneity and complex tumor microenvironments keep realization probability strictly below fifty percent. Probability: +32%. Expected impact: +58%.
Automated microfluidic synthesis cost breakthrough: Engineering breakthroughs in automated desktop microfluidics and synthetic molecular biology could slash individualized therapy turnaround times from six weeks to ten days by 2029. Reducing bespoke production costs by 70% transforms personalized therapeutics from an artisanal hospital procedure into a scalable, high-margin commercial reality, expanding operating margins by over 1,500 basis points. Rigorous good manufacturing compliance requirements keep probability in the tail range. Probability: +24%. Expected impact: +42%.

What to monitor

Thesis watchpoints

-- Full INTerpath-001 overall survival hazard ratio disclosed at or below 0.65 across 2027 confirms platform pricing power.

Key insights

Quarterly operating cash burn exceeding $600 million through 2027 signals rapid liquidity drain, accelerating multiple compression.
Commercial biopsy-to-infusion cycle times exceeding six weeks during 2028 commercial rollout mandates immediate downward valuation recalibration.

Company Financial Analysis

Moderna Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Moderna's income statement reflects the severe reality of a post-pandemic financial transition. Following historic peaks, fiscal 2025 revenue fell 39.2% to $1.94 billion, producing a net loss of $2.82 billion. Through the second quarter of 2026, trailing twelve-month revenue stabilized near $2.23 billion, but operating losses remained staggering at $3.32 billion. This persistent deficit demonstrates that headline commercial approvals cannot instantly replace lost pandemic revenues. While management has trimmed research spending to slow the cash bleed, commercial receipts from seasonal vaccines remain insufficient to cover ongoing late-stage clinical trials. Until cancer therapies reach the market, the enterprise remains heavily reliant on pre-existing liquidity reserves to fund operations.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 1.9B	USD -2.8B	USD -2.1B
2024	USD 3.2B	USD -3.6B	USD -4.1B
2023	USD 6.8B	USD -4.7B	USD -3.8B
2022	USD 18.9B	USD 8.4B	USD 4.6B
2021	USD 17.7B	USD 12.2B	USD 13.3B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	8.7x	Annual	Native	USD / USD
2021	9.0x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability metrics illustrate extreme negative operating leverage following the loss of pandemic scale. Gross margin stabilized near 55.3% in fiscal 2025 as inventory write-offs ceased, yet operating margins remained deeply underwater at negative 158%. Fixed research and clinical infrastructure costs heavily outweigh reduced commercial vaccine receipts. This margin gap proves that manufacturing economics differ drastically between mass vaccines and customized therapeutics. Personalized cancer treatments require individual tumor sequencing and custom synthesis, creating substantial unit costs. Operating margins cannot sustainably inflect until high-margin oncology products reach commercial scale and absorb fixed corporate overhead.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -3.1B	-158.1%	-145.2%
2024	USD -3.9B	-123.3%	-111.3%
2023	USD -4.2B	-61.9%	-68.8%
2022	USD 9.4B	49.9%	44.3%
2021	USD 13.3B	75.0%	68.8%

Balance sheet and leverage

AI Review

Moderna's balance sheet retains optical short-term liquidity while enduring steady underlying erosion. Stockholders' equity contracted from $19.12 billion in 2022 to $8.65 billion in 2025 under persistent operating deficits. Total cash and investments stood near $6.9 billion in mid-2026 before being augmented by a $2.6 billion zero-coupon convertible notes offering. While this financing extends the cash runway into 2028 without immediate dilution, it introduces long-term obligations alongside an existing $1.5 billion credit facility. Headline cash provides short-term safety, but persistent cash burn leaves the company vulnerable if commercial milestones encounter regulatory delays or clinical setbacks.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 1.9B	USD 5.8B	USD 679M net cash	3.29x
2024	USD 747M	USD 7B	USD 1.2B net cash	3.67x
2023	USD 1.2B	USD 8.6B	USD 1.7B net cash	3.42x
2022	USD 1.2B	USD 9.9B	USD 2B net cash	2.73x
2021	USD 916M	USD 10.7B	USD 5.9B net cash	1.76x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has shifted from aggressive post-pandemic facility expansion toward strict capital rationing. Capital expenditures dropped from 32.9% of revenue in 2024 to 9.88% in 2025 as major manufacturing facilities were completed. Annual research and development spending fell 31.1% in 2025 to $3.13 billion as non-core exploratory pipelines were discontinued. This disciplined spending pivot preserves vital cash reserves while concentrating investment on pivotal Phase 3 programs. However, tailoring treatments for individual cancer patients will eventually demand specialized automation. While current restraint protects near-term solvency, underinvesting in high-throughput manufacturing could create future bottlenecks when personalized cancer therapies enter broad commercial distribution.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 192M	USD 3.1B
2024	USD 1.1B	USD 4.5B
2023	USD 707M	USD 4.8B
2022	USD 400M	USD 3.3B
2021	USD 284M	USD 2B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	SELL_ALL	-316	-24.1%	Not available	ORIGINAL
5Y	NEUTRAL	-5	+13.5%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	135.56	138.42	144.8	14
+6M	March 18, 2027	122	125.98	137.56	14
+9M	June 18, 2027	104.92	122.48	137.99	14
+1Y	September 18, 2027	93.38	116.91	132.85	14
+15M	December 18, 2027	79.37	116.72	143.17	14
+18M	March 18, 2028	69.85	115.76	150.32	14
+21M	June 18, 2028	75.43	119.31	162.35	14
+2Y	September 18, 2028	63.37	119.71	173.71	14
+27M	December 18, 2028	51.96	122.42	192.82	14
+30M	March 18, 2029	47.8	123.36	198.61	14
+33M	June 18, 2029	49.71	129.99	216.48	14
+3Y	September 18, 2029	52.2	134.79	229.47	14
+39M	December 18, 2029	55.33	140.91	247.83	14
+42M	March 18, 2030	59.21	143.4	257.74	14
+45M	June 18, 2030	61.57	150.76	283.52	14
+4Y	September 18, 2030	63.42	154.57	297.69	14
+51M	December 18, 2030	64.69	160.68	318.53	14
+54M	March 18, 2031	65.34	163.92	328.09	14
+57M	June 18, 2031	67.3	169.88	347.77	14
+5Y	September 18, 2031	68.64	174.84	361.68	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The synthesized consensus is anchored by a compelling, independently supported empirical pattern: while positive Phase 3 INTerpath-001 melanoma data validates messenger RNA outside infectious disease, the market's parabolic re-rating to 27.4 times sales severely disconnects from underlying commercial economics. Correlated assumptions across optimistic submissions mistakenly treat clinical validation as immediate commercial cash generation, overlooking bespoke manufacturing logistics, multi-week turnaround times, and equal partnership profit sharing. Conversely, the strongest credible contrarian insight confirms that recent non-dilutive zero-coupon convertible financing eliminates imminent solvency distress, extending runway toward 2028 commercialization. Relative weights heavily reward submissions grounded in primary SEC filings, audited balance sheets, and realistic unit cost-of-goods calculations, while downweighting models that assume either catastrophic liquidity collapse or frictionless, software-like margin expansion. Material unresolved uncertainty persists regarding overall survival durability in oncology and regulatory stability across domestic vaccine schedules, dictating a path characterized by near-term multiple compression followed by measured, execution-driven recovery.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight12.0/100

Outstanding forensic analysis incorporating recent zero-coupon convertible note mechanics, capped calls, and precise dilution thresholds. It correctly reconciles commercial partnership economics with elevated discount rates, establishing an exceptionally sound risk-adjusted baseline path.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight12.0/100

Exemplary primary source grounding in SEC filings, Form 10-Q disclosures, and shared partnership terms. It rigorously differentiates headline clinical efficacy from per-share distributable cash flow, offering the most causally consistent path among all submissions.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight10.0/100

Thoroughly articulates the temporal lag between headline clinical readouts and commercial cash realization. Its balanced appraisal of combination respiratory portfolio defense versus bespoke production margin compression provides robust, evidence-backed forecasting value.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight8.0/100

Strong forensic identification of bespoke manufacturing cost structures, 50% partnership profit splits, and credit facility covenants. It anchors grounded skepticism regarding personalized therapy margins, though its severe near-term debt distress scenario is slightly overstated post-convertible issuance.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight8.0/100

Delivers rigorous scrutiny of commercial distribution barriers in seasonal influenza against established pharmaceutical incumbents. While its long-term operating margin normalization is slightly optimistic, its near-term multiple compression thesis is well supported by commercial realities.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight7.0/100

Offers valuable geopolitical and institutional analysis regarding international sovereign biosecurity procurement and domestic regulatory friction. Its bull-case recovery relies heavily on smooth commercial oncology execution, somewhat underestimating initial turnaround bottlenecks across cancer centers.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight7.0/100

Demonstrates sound macro awareness regarding elevated hurdle rates and discount penalties on long-duration assets. However, its terminal path projects an aggressive valuation recovery that minimizes prolonged competitive pressures across respiratory markets and bespoke production hurdles.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight7.0/100

Provides a balanced view of platform modularity alongside realistic appraisal of six-week vein-to-vein turnaround logistics. The long-term return trajectory slightly overstates margin expansion velocity across non-melanoma indications, necessitating a calibrated moderate weight.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight6.0/100

Presents an astute contrast between frictionless digital software scaling and physical manufacturing bottlenecks in bespoke neoantigen synthesis. Its later-stage path relies on rapid technological breakthroughs in automated microfluidics that remain unproven, limiting its weight.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight6.0/100

Provides incisive forensic examination of clinical trial effect reporting, noting the absence of mature overall survival hazard ratios in initial press disclosures. It appropriately models post-euphoria multiple contraction, though its outer-year recovery is somewhat abrupt.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight5.0/100

Correctly identifies multiple mean-reversion risks and balance sheet equity erosion under sustained research expenditure. It somewhat overstates the probability of dilutive equity financing by overlooking the cash runway afforded by recent convertible debt issuance.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight5.0/100

Solid owner-earnings discipline emphasizing negative cash conversion, idle manufacturing charges, and restrictive debt covenants. However, it takes an overly conservative view of pipeline optionality across latent virus and respiratory combinations, limiting its weight.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight4.0/100

This report correctly highlights acute owner earnings deficits, ongoing book value depletion, and extreme sales multiple disconnects. However, its excessively punitive liquidation framing underweights validated neoantigen trial success and non-dilutive government partnerships, warranting a modest weighting.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight3.0/100

Provides a useful thermodynamic critique of fixed cost structures against crashing endemic vaccine volumes. Nonetheless, it heavily discounts late-stage clinical oncology derisking and assumes extreme competitive displacement, justifying a minimal relative allocation.

Skip to references

Research Provenance

References & Context

This Moderna consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 141 deduplicated sources retained for this batch.

01MFLUSIVA | FDAfda.gov
022026 Moderna NPSsec.gov
038-Ksec.gov
04Form 8-Ksec.gov
05Moderna, Inc. - Form 8-K - FY2026sec.gov
06mrna-20251231sec.gov
07www.sec.govsec.gov
08Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma - Merck.commerck.com
09Cancer vaccine win restores Wall Street’s faith in Moderna | BioPharma Divebiopharmadive.com
10Merck and Moderna's Intismeran Autogene Plus Pembrolizumab Meets Endpoints in Phase 3 Melanoma Trial | BioPharm Internationalbiopharminternational.com
11Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future - BioSpacebiospace.com
12The State of US Vaccine Policy — Feb 19, 2026 | CIDRAPcidrap.umn.edu
13The State of US Vaccine Policy — May 28, 2026 | CIDRAPcidrap.umn.edu
14ACIP: HHS rewrites rules governing key CDC vaccine committee | CNNcnn.com
15CDC vaccine committee drops push to stop recommending mRNA Covid-19 shots, for now | CNNcnn.com

And 126 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.